Friday, July 10, 2026

Drug profile · INN

rucaparib

rucaparib (RUBRACA) is a parp 1, 2 and 3 inhibitor.

EMA: approved Antineoplastic and immunomodulating agents (L01) L01XX
Patents linked 0
Pipeline programs 5
News articles 0
Drug details — rucaparib
Class
Antineoplastic and immunomodulating agents (L01)
Route
Patents
0
Programs
5
Data quality
0.83

Quick answer

rucaparib (RUBRACA) is a parp 1, 2 and 3 inhibitor.

Key facts

INN rucaparib
Brand RUBRACA
Mechanism PARP 1, 2 and 3 inhibitor
Target PARP 1, 2 and 3
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01XX

Mechanism of action

PARP 1, 2 and 3 inhibitor

Primary target: PARP 1, 2 and 3

Approval history

Authority Status Date
EMA approved

Pipeline programs

  1. CO-338-087 Phase 3 · pharma& · Ovarian epithelial cancer, Malignant peritoneal neoplasm, ad
  2. Rucaparib Phase 3 · pharma& · Ovarian Cancer
  3. CA209-8TT Phase 2 · Bristol-Myers Squibb Australia · Pan tumor
  4. MITO 25.1 Phase 2 · Telethon Foundation · Advanced (stage III B-C-IV) ovarian, primary peritoneal and
  5. Rucaparib Phase 2 · United Therapeutics Europe · Cervical Cancer

Related & competitor drugs

  1. abiraterone acetate Antineoplastic and immunomodulating agents (L02)
  2. anagrelide Antineoplastic and immunomodulating agents (L01)
  3. apremilast Antineoplastic and immunomodulating agents (L04)
  4. arsenic trioxide Antineoplastic and immunomodulating agents (L01)
  5. axitinib Antineoplastic and immunomodulating agents (L01)
  6. azacitidine Antineoplastic and immunomodulating agents (L01)

Frequently asked questions

What is rucaparib?

rucaparib (RUBRACA) is a parp 1, 2 and 3 inhibitor.

What is the brand name for rucaparib?

RUBRACA is a marketed brand name for rucaparib. Check FDA Drugs@FDA for the current US label holder and prescribing information.